Oral cibenzoline reduces postoperative atrial fibrillation in coronary artery bypass grafting.
OBJECTIVE
The objective of the present study was to investigate the effectiveness of postoperative oral administration of cibenzoline for the prevention of atrial fibrillation (AF) in coronary artery bypass grafting (CABG).


METHODS
A total of 39 patients who underwent isolated CABG from September 2000 to February 2001 and who took oral cibenzoline (300 mg per day for 10 days beginning immediately after surgery) were compared to 59 patients who underwent surgery in our department 8 months prior to the study and who did not take cibenzoline for incidence of postoperative AF. Exclusion criteria encompassed age (>80 years), low ejection fraction (<30%), high serum creatinine level (>2.0 mg/dL), and history of supraventricular arrhythmia with or without treatment by anti-arrhythmic drugs.


RESULTS
Postoperative AF occurred in 2 patients in the cibenzoline group (2/35, 5.7%) and 20 patients in the control group (20/59, 33.9%). There were significant differences in the incidence of postoperative AF (p = 0.002). Multivariate analysis revealed that the administration of cibenzoline reduced the incidence of AF significantly, and that a large number of bypass grafts significantly contributed to postoperative AF in CABG. The number of bypass grafts was significantly larger in the cibenzoline group, indicating that cibenzoline administration significantly suppresses the incidence of AF after CABG in high-risk patients.


CONCLUSIONS
Postoperative administration of oral cibenzoline for 10 days is one effective method for the prevention of AF after CABG.
Kuriu
Kazuyuki
K
Department of Cardiothoracic Surgery, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan.
Tanaka
Hiroyuki
H
Hirao
Kenzo
K
Makita
Satoru
S
Ito
Fusahiko
F
Mizuno
Tomohiro
T
Tabuchi
Noriyuki
N
Arai
Hirokuni
H
Sunamori
Makoto
M
D000284:Administration, Oral; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D003324:Coronary Artery Disease / Q000453:epidemiology / Q000601:surgery*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents; D007093:Imidazoles; C032151:cifenline
Chest. 2002 Apr;121(4):1203-10
11948054
Crit Care Med. 1993 Oct;21(10):1474-8
8403955
Drugs. 1992 May;43(5):734-59
1379150
JAMA. 1996 Jul 24-31;276(4):300-6
8656542
N Engl J Med. 1997 Dec 18;337(25):1785-91
9400034
Ann Thorac Surg. 1993 Sep;56(3):539-49
8379728
Eur Heart J. 1984 Feb;5(2):108-14
6723683
Prog Cardiovasc Dis. 1989 Mar-Apr;31(5):367-78
2646657
Ann Thorac Surg. 1997 Oct;64(4):1113-9
9354537
J Thorac Cardiovasc Surg. 1991 Jan;101(1):56-65
1986170
Transplant Proc. 1993 Feb;25(1 Pt 2):1613-7
8442211
Jpn Circ J. 1999 Jan;63(1):1-12
10084381
Am Heart J. 1992 May;123(5):1225-8
1575138
Am J Cardiol. 1989 May 1;63(15):1058-64
2495710
J Cardiovasc Pharmacol. 1999 Jul;34(1):53-9
10413067
J Cardiovasc Pharmacol. 1989 Jul;14(1):88-95
2475722
Chest. 1993 May;103(5):1515-9
8486036
Eur J Cardiothorac Surg. 1987;1(3):165-8
3272807
Circulation. 1996 Aug 1;94(3):390-7
8759081
J Am Coll Cardiol. 1999 Aug;34(2):334-9
10440141
Circulation. 1991 Nov;84(5 Suppl):III236-44
1682069
J Thorac Cardiovasc Surg. 1990 Sep;100(3):338-42
2391970
Circulation. 2001 Oct 23;104(17):2118-50
11673357
Eur Heart J. 1994 Sep;15(9):1274-8
7982430
Ann Thorac Surg. 1985 Apr;39(4):336-9
3885884
Am J Cardiol. 1990 Mar 1;65(9):628-32
2309633
Heart. 2003 Oct;89(10):1134-7
12975397